Application of Box-Behnken Design in the Preparation, Optimization, and In Vitro Evaluation of Self-Assembly-Based Tamoxifen- and Doxorubicin-Loaded and Dual Drug-Loaded Niosomes for Combinatorial Breast Cancer Treatment

J Pharm Sci. 2019 Aug;108(8):2643-2653. doi: 10.1016/j.xphs.2019.03.020. Epub 2019 Mar 21.

Abstract

This study was developed with the objective to prepare self-assembled niosomes to support sufficient entrapment and sustained drug release of the drugs having different solubility and mechanisms. In the current work, Tamoxifen- and Doxorubicin-loaded niosomes were prepared for combinatorial breast cancer treatment with statistical optimization by Box-Behnken experimental design. Atomic force microscopy revealed a spherical shape morphology of the niosomes. The entrapment efficiencies for the drugs were found to be 74.3% and 72.7% for Tamoxifen and Doxorubicin, respectively. The drug release experiments at different pH values displayed a sustained release up to 3 days. Fourier transform infrared spectroscopy and differential scanning calorimetry showed a robust drug-excipient compatibility. The niosomes were stable over a period of 6 months with no significant changes. In vitro cytotoxicity studies on MCF-7 cell line showed a 15-fold improvement (0.01 μg per mL) and a better synergistic effect of the niosomes in comparison to the free drug combination (0.15 μg per mL). Moreover, the nanocarrier uptake studies by fluorescence microscopy and flow cytometry showed a good distribution and greater uptake of the niosomes throughout the cells. These results suggest a profound therapeutic application of the niosomes for a combinatorial breast cancer treatment.

Keywords: Synergism; box-behnken; breast cancer; combinatorial drug delivery; niosomes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / chemistry
  • Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Breast Neoplasms / drug therapy*
  • Cell Survival / drug effects
  • Delayed-Action Preparations / chemistry*
  • Doxorubicin / administration & dosage*
  • Doxorubicin / chemistry
  • Doxorubicin / pharmacokinetics
  • Doxorubicin / pharmacology
  • Drug Liberation
  • Female
  • Humans
  • MCF-7 Cells
  • Particle Size
  • Solubility
  • Tamoxifen / administration & dosage*
  • Tamoxifen / chemistry
  • Tamoxifen / pharmacokinetics
  • Tamoxifen / pharmacology

Substances

  • Antineoplastic Agents
  • Delayed-Action Preparations
  • Tamoxifen
  • Doxorubicin